近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Zhang, Lei, Coombes, Jeff, Pascoe, Elaine M., Badve, Sunil V., Dalziel, Kim, Cass, Alan, Clarke, Philip, FerrarI, Paolo, McDonald, Stephen P., Morrish, Alicia T., Pedagogos, Eugenie, Perkovic, Vlado, Reidlinger, Donna, Scaria, Anish, Walker, Rowan, Vergara, Liza A., Hawley, Carmel M. and Johnson, David W. (2016) The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: sub-study of the HERO trial.. Redox Report, 21 1: 14-23. doi:10.1179/1351000215Y.0000000022 Badve, Sunil V., Zhang, Lei, Coombes, Jeff S., Pascoe, Elaine M., Cass, Alan, Clarke, Philip, Ferrari, Paolo, McDonald, Stephen P., Alicia T. Morrish, Eugenie Pedagogos, Vlado Perkovic, Donna Reidlinger, Anish Scaria, Rowan Walker, Liza A. Vergara, Carmel M. Hawley, David W. Johnson and and on behalf of the HERO Study Collaborative Group (2015) Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Canadian Journal of Kidney Health and Disease, 2 33: 1-10. doi:10.1186/s40697-015-0066-5 Johnson, David W., Pascoe, Elaine M., Badve, Sunil V., Dalziel, Kim, Cass, Alan, Clarke, Philip, Ferrari, Paolo, McDonald, Stephen P., Morrish, Alicia T., Pedagogos, Eugenie, Perkovic, Vlado, Reidlinger, Donna, Scaria, Anish, Walker, Rowan, Vergara, Liza A., Hawley, Carmel M., on behalf of the HERO Study Collaborative Group and Fassett, Rob (2015) A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the handling erythropoietin resistance with oxpentifylline (HERO) trial. American Journal of Kidney Diseases, 65 1: 49-57. doi:10.1053/j.ajkd.2014.06.020 Morrish, A.T., Hawley, C.M., Johnson, D.W., Badve, S.V., Perkovic, V., Reidlinger, D.M. and Cass, A. (2014) Establishing a clinical trials network in nephrology: Experience of the Australasian Kidney Trials Network. Kidney International, 85 1: 23-30. doi:10.1038/ki.2013.391